Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED SOLID TUMOR

Trial Profile

DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED SOLID TUMOR

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gedatolisib (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Endometrial cancer; Lung cancer; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jul 2021 Following the first 9 patients treated with the above mentioned schedule, the study was amended, dose of Gedatolisib 110mg and 130 mg has added in the treatment.
    • 15 Jul 2021 Results published in the Clinical Cancer Research
    • 21 Sep 2020 According to results presented at the 45th European Society for Medical Oncology Congress, Carboplatin was initially administered at AUC5 on day 8 and Paclitaxel at 80 mg/m2 on day 8, 15 and 22 and after a protocol amendment on day 1 and day 1, 8 and 15 respectively, in 28d cycles.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top